Published in Br J Cancer on January 16, 2006
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist (2011) 1.30
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer (2007) 0.99
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs (2013) 0.88
Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways. Clin Cancer Res (2013) 0.84
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther (2016) 0.82
Role of erlotinib in the management of pancreatic cancer. Ther Clin Risk Manag (2006) 0.79
Successful treatment of epidermal growth factor receptor inhibitor-induced periungual inflammation with adapalene. Case Rep Dermatol (2011) 0.78
Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs (2015) 0.76
Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses. Dermatol Ther (Heidelb) (2015) 0.75
Psoriasis induced by trastuzumab (herceptin®). Ann Dermatol (2013) 0.75
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim (1999) 4.93
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol (2002) 2.25
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem (2003) 1.93
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol (2000) 1.67
Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol (2003) 1.66
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol (2004) 1.49
The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer (2001) 1.46
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol (2001) 1.44
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist (2004) 1.42
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res (2003) 1.23
EGF-R dependent regulation of keratinocyte survival. J Cell Sci (1997) 1.23
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) (2003) 1.17
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia (2001) 1.14
Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res (2002) 1.06
Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res (2001) 1.04
Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. Oncogene (1997) 1.03
Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res (2003) 1.01
Signal events: Cell signal transduction and its inhibition in cancer. Oncologist (2003) 1.00
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br J Cancer (2003) 0.93
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol (2001) 0.91
EGFR family-mediated signal transduction in the human keratinocyte cell line HaCaT. Exp Cell Res (1999) 0.85
Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res (2003) 0.83
Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol (2004) 0.80
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Kidney transplantation under FK 506. JAMA (1990) 7.45
Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med (1994) 5.14
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA (1991) 4.57
Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A (1996) 4.11
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology (1994) 3.89
The sexual and reproductive behavior of American women, 1982-1988. Fam Plann Perspect (1991) 3.84
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India (2007) 3.52
Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Who should fill the care gap in HIV disease? Lancet (1993) 3.26
Recommendations on the use of exercise testing in clinical practice. Eur Respir J (2007) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Differences in teenage pregnancy rates among five developed countries: the roles of sexual activity and contraceptive use. Fam Plann Perspect (2002) 3.12
The need for prenatal care in the United States: evidence from the 1980 National Natality Survey. Fam Plann Perspect (1987) 2.93
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Macrophage activation syndrome: experience from a tertiary referral centre. J Assoc Physicians India (2007) 2.73
Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A (1974) 2.66
Timing of prenatal care in the United States: how accurate are our measurements? Health Serv Res (1987) 2.61
Pneumocystis carinii infection in patients of AIDS in India. J Assoc Physicians India (1993) 2.57
Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet (1992) 2.55
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. J Postgrad Med (2006) 2.43
Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39
Bacteriological study of Indian cheese (paneer) sold in Chandigarh. Indian J Med Microbiol (2007) 2.34
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Development and mapping of microsatellite (SSR) markers in wheat. Theor Appl Genet (2005) 2.27
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM (2010) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res (2001) 2.22
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther (2014) 2.18
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15
Cardiovascular risk assessment of South Asians in a religious setting: a feasibility study. Int J Clin Pract (2011) 2.12
Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J (2009) 2.10
Sexually transmitted diseases among adolescents in developed countries. Fam Plann Perspect (2000) 2.10
Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int J Cancer (1974) 2.10
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
Intracellular forms of Epstein-Barr virus DNA in human tumour cells in vivo. Nature (1976) 2.10
Crystalline fraction I protein: preparation in large yield. Science (1972) 2.09
The incidence of abortion worldwide. Int Fam Plann Persp (1999) 2.09
The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell (1989) 2.07
Reduction in radiation exposure during coronary angiography. Cathet Cardiovasc Diagn (1990) 2.03
Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology (1995) 2.02
Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci U S A (1994) 2.02
DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1973) 2.02
Cystic lymphangioma in children: report of 32 cases including lesions atrrare sites. Surgery (1971) 2.02
Instructing subjects to make a voluntary response reveals the presence of two components to the audio-vocal reflex. Exp Brain Res (2000) 2.01
The general practitioner and human immunodeficiency virus infection: an insight into patients' attitudes. J R Coll Gen Pract (1989) 1.96
Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96
BCL-6 expression during B-cell activation. Blood (1996) 1.95
Multiplex PCR assay for simultaneous detection and differentiation of Mycobacterium tuberculosis, Mycobacterium avium complexes and other Mycobacterial species directly from clinical specimens. J Appl Microbiol (2009) 1.90
Changing emphases in sexuality education in U.S. public secondary schools, 1988-1999. Fam Plann Perspect (2001) 1.90
Contraceptive failure in the first two years of use: differences across socioeconomic subgroups. Fam Plann Perspect (2001) 1.90
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87
Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene (2006) 1.79
Reversible cold inactivation and heat reactivation of RuDP carboxylase activity of crystallized tobacco fraction I protein. Biochem Biophys Res Commun (1971) 1.79
The challenges of involving traditional healers in HIV/AIDS care. Int J STD AIDS (2006) 1.78
Comparative evaluation of fungal, tubercular, and pyogenic brain abscesses with conventional and diffusion MR imaging and proton MR spectroscopy. AJNR Am J Neuroradiol (2007) 1.78
Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int J Tuberc Lung Dis (2003) 1.76
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Trends in HIV testing and recording of HIV status in the UK primary care setting: a retrospective cohort study 1995-2005. Sex Transm Infect (2009) 1.74
Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J (1989) 1.74
Investigating the thyroid nodule. BMJ (2009) 1.73
Prospective audit of surgery for varicose veins. Br J Surg (1997) 1.73
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71
Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax. J Biol Chem (2001) 1.70
A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol (2000) 1.70
Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev (2004) 1.70
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
Myasthenic crisis: a retrospective study. Neurol India (2004) 1.68
Identification of non-heme diiron proteins that catalyze triple bond and epoxy group formation. Science (1998) 1.67
Arteriovenous malformation of knee masquerading as juvenile arthritis. Scand J Rheumatol (1998) 1.65
HIV infection and sexually transmitted diseases in a referral STD centre in south India. Sex Transm Infect (1999) 1.65
The role of the general practitioner in the community care of people with HIV infection and AIDS: a comparative study of high- and low-prevalence areas in England. Br J Gen Pract (1998) 1.65
A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther (2014) 1.64
Community care reforms: early implications for general practice. Br J Gen Pract (1994) 1.63
Isolated lipid abnormalities in rural and urban normotensive and hypertensive north-west Indians. J Assoc Physicians India (2003) 1.62
Stress and vulnerability to posttraumatic stress disorder in children and adolescents. Am J Psychiatry (2000) 1.61
The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60
Physico-chemical and pasting properties of starch from stored potato tubers. J Food Sci Technol (2010) 1.60
Accuracy and applicability of the revised WHO classification (2009) of dengue in children seen at a tertiary healthcare facility in northern India. Infection (2013) 1.59
Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet (2012) 1.58
Lipoprotein (a) and lipid levels in young patients with myocardial infarction and their first-degree relatives. Indian Heart J (2001) 1.57
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56
Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. Int J Lab Hematol (2007) 1.56
Efficacy of sutureless and glue free limbal conjunctival autograft for primary pterygium surgery. Nepal J Ophthalmol (2012) 1.56
Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology (1993) 1.55
An unusual case of temporal encephalocele. Childs Nerv Syst (1989) 1.55
The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med (2008) 1.55
Ambiguous coronary angiography: clinical utility of intravascular ultrasound. Cathet Cardiovasc Diagn (1992) 1.54
The physical and chemical stability of anti-tuberculosis fixed-dose combination products under accelerated climatic conditions. Int J Tuberc Lung Dis (2004) 1.54